News and Events

News Medical: High DPP3 concentration in the blood predicts multiple organ failure in burn patients

The Cardiac Depressant Factor DPP3 is Predicting Organ Failure in Burn Patients

Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.

READ MORE ↵


European Biotechnology: 4TEEN4’s DPP3 predicts burn mortality

Dépret F et al. on Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients

Biopharmapress: Combating Sepsis Mortality

European Biotechnology: Fighting sepsis mortality

BioWorld: 4TEEN4 closes $8M A round to test first-in-class cardiogenic shock drug

VC-Magazin: 4TEEN4 Pharmaceuticals sammelt 6.9 Mio. EUR ein

LABIOTECH: German Biotech Raises €7M Series A to Treat Acute Heart Failure

Biotech Startup 4TEEN4 Pharmaceuicals Closes EUR 7 Million Series A Financing

Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.

READ MORE ↵


LABIOTECH: Top Cardiology Biotech News from the ESC Conference 2019

transkript: Berliner Seriengründer präsentiert neues Projekt

European Biotechnology: DPP3 triggers myocardial depression

LABIOTECH: 4TEEN4 Pharmaceuticals reports first results on Procizumab, a novel therapeutic anti-DPP3 antibody for treatment of acute myocardial depression.

4TEEN4 Pharmaceuticals reports first results on Procizumab, a novel therapeutic anti-DPP3 antibody for treatment of acute myocardial depression.

4TEEN4 Pharmaceuticals GmbH today for the first time reported preclinical data on its lead product Procizumab, a therapeutic antibody targeting circulating Dipeptidyl Peptidase 3 (DPP3) for the treatment of patients with acute myocardial depression including acute heart failure and cardiogenic shock.

READ MORE ↵


Deniau B et al. on Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics

Takagi K et al. on Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial

Kaufmann P et al. on A novel and highly efficient purification procedure for native human dipeptidyl peptidase 3 from human blood cell lysate

Rehfeld L et al. on Novel Methods for the Quantification of Dipeptidyl Peptidase 3 (DPP3) Concentration and Activity in Human Blood Samples